Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn wins FDA approval for Akten ophthalmic gel 3.5%
The new drug application (NDA) was filed on June 29, 2007 following the results from a randomized, placebo controlled, Phase III clinical trial in 209 subjects who met
The new drug application (NDA) was filed on June 29, 2007 following the results from a randomized, placebo controlled, Phase III clinical trial in 209 subjects who met
Under the terms of the agreement, Cenomed acquired from TorreyPines Therapeutics the worldwide development rights to three compounds, phenserine, Posiphen and bisnorcymcerine, for chemical defense and counterterrorism defense.
The expansion phase of the study allows the clinical sites to enroll additional patients meeting the enrollment criteria to evaluate safety and efficacy across a range of related
The licensing agreement provides Pharmacells access to Moraga’s proprietary adult stem cell technology for banking its blastomere-like stem cells (BLSCs) that have been isolated, processed, and cryopreserved from
As CFO, Mr Choong will oversee the company’s various financial functions, including finance and accounting, financial planning and analysis, regulatory and risk management, and facilities development. Mr Choong
Ceplene is to be administered in conjunction with low-dose interleukin-2 (IL-2). The approval allows Ceplene to be marketed in the 27 member states of the EU, as well
The data presented from three open-label, randomized studies in healthy men and women showed that showering one hour or later, or the application of sunscreen 30 minutes before
NMT believes that it is the first company to complete enrollment of a prospective, multi-center, randomized, controlled study that examines the potential relationship between patent foramen ovale (PFO)
Dr Gallagher joins Calistoga Pharmaceuticals after recently serving as president and CEO of Metastatix, a private oncology company. Prior to that, Dr Gallagher held senior leadership roles at
xTAG respiratory viral panel (RVP) is a unique test that, from one patient sample, simultaneously detects the 18 respiratory viruses and subtypes that are responsible for the majority